Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation
- PMID: 27038710
- DOI: 10.1016/j.ijcard.2016.03.039
Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation
Abstract
Background: According to recent clinical trial data, correction of iron deficiency with intravenous (i.v.) iron has favorable outcomes on cardiac function. We evaluated whether i.v. iron treatment of anemic rats has favorable effect on the left ventricular (LV) performance and remodeling and the role of oxidative/nitrosative stress and inflammation in the process.
Methods: After weaning, Sprague-Dawley rats were fed low iron diet for 16weeks, after which the treatment group received five weekly doses of i.v. iron sucrose (10mg Fe/kg body weight). Echocardiography of LV was performed and hematology parameters were assessed before treatment (baseline, day 0) and at the end of the study (day 29). On day 29, rats were sacrificed and extracellular expansion and fibrosis in LV and interventricular septum were evaluated together with oxidative/nitrosative stress, pro-inflammatory, and repair process markers.
Results: Although iron sucrose treatment did not fully correct the anemia, it reversed anemia-induced cardiac remodeling as indicated by echocardiographic and tissue Doppler parameters. Treatment with iron sucrose also prevented anemia-induced myocardial fibrosis as indicated by extracellular expansion and fibrosis markers. Anemia-induced inflammation was prevented by iron sucrose as indicated by the levels of proinflammatory (TNF-α, NF-κB65) and repair process markers (HSP27, HSP70). In addition, iron sucrose treatment significantly reduced (p<0.01) anemia-induced oxidative and nitrosative stress.
Conclusion: Intravenous iron sucrose treatment reversed anemia-induced remodeling of LV, prevented myocardial fibrosis, and improved cardiac function by attenuating oxidative/nitrosative stress and inflammation in the heart.
Keywords: Cardiac function; Cardiac remodeling; Intravenous iron sucrose; Oxidative stress; Rat.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds.Drug Des Devel Ther. 2017 Aug 1;11:2251-2263. doi: 10.2147/DDDT.S132612. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28814833 Free PMC article.
-
Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.Inflamm Allergy Drug Targets. 2012 Feb;11(1):66-78. doi: 10.2174/187152812798889358. Inflamm Allergy Drug Targets. 2012. PMID: 22309085 Free PMC article.
-
Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator.Biometals. 2015 Apr;28(2):279-92. doi: 10.1007/s10534-015-9822-3. Epub 2015 Jan 22. Biometals. 2015. PMID: 25609135
-
Acute injury with intravenous iron and concerns regarding long-term safety.Clin J Am Soc Nephrol. 2006 Sep;1 Suppl 1:S19-23. doi: 10.2215/CJN.01420406. Clin J Am Soc Nephrol. 2006. PMID: 17699372 Review.
-
Is intravenous iron sucrose the treatment of choice for pregnant anemic women?J Obstet Gynaecol Res. 2013 Mar;39(3):619-26. doi: 10.1111/j.1447-0756.2012.02033.x. Epub 2012 Nov 20. J Obstet Gynaecol Res. 2013. PMID: 23167561 Review.
Cited by
-
Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD.Sci Rep. 2023 Oct 26;13(1):18401. doi: 10.1038/s41598-023-44578-6. Sci Rep. 2023. PMID: 37884522 Free PMC article. Clinical Trial.
-
Iron Sucrose: A Double-Edged Sword in High Phosphate Media-Induced Vascular Calcification.Calcif Tissue Int. 2021 Jun;108(6):798-807. doi: 10.1007/s00223-020-00804-1. Epub 2021 Jan 13. Calcif Tissue Int. 2021. PMID: 33439323
-
Myocardial Performance Improvement After Iron Replacement in Heart Failure Patients: The IRON-PATH II Echo-Substudy.J Clin Med. 2025 Jun 7;14(12):4048. doi: 10.3390/jcm14124048. J Clin Med. 2025. PMID: 40565791 Free PMC article.
-
Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial.ESC Heart Fail. 2020 Dec;7(6):4222-4230. doi: 10.1002/ehf2.13053. Epub 2020 Oct 11. ESC Heart Fail. 2020. PMID: 33040491 Free PMC article.
-
Structural and functional abnormalities in iron-depleted heart.Heart Fail Rev. 2019 Mar;24(2):269-277. doi: 10.1007/s10741-018-9738-4. Heart Fail Rev. 2019. PMID: 30284070 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous